• CSPC said the FDA cleared Corbus’s CRB-701 (SYS 6002) to start TEMPO-1, a registrational trial in second-line oropharyngeal cancer.
• The randomized study will compare CRB-701 with investigator’s-choice monotherapy; primary endpoints are objective response rate and overall survival.
• Corbus expects to begin patient enrollment in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260729-12260769), on July 29, 2026, and is solely responsible for the information contained therein.